<DOC>
	<DOCNO>NCT02481960</DOCNO>
	<brief_summary>A study demonstrate safety , feasibility intraparenchymal injection irinotecan hydrochloride drug-eluting bead treatment recurrent high grade glioma ( HGG ) .</brief_summary>
	<brief_title>Study Intraparenchymal Therapy With Irinotecan Drug Eluting Beads Adjunct Recurrent Surgically Resectable High Grade Glioma</brief_title>
	<detailed_description>CM-BC2 , irinotecan hydrochloride drug-eluting bead , investigational product develop direct injection tumor resection margin , patient recurrent high grade glioma ( HGG ) , order prevent delay tumor progression recurrence . Patients enrol receive CM-BC2 follow surgical resection recurrent high grade glioma attend specify study visit 6 month post surgery .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologically confirm diagnosis Glioblastoma Multiforme ( GBM ) ( World Health Organization grade III IV ) 2 . Patient consider good candidate resection estimate life expectancy least 12 week estimate Principal Investigator designee . The decision opt resection recurrence must independent study selection . 3 . Tumour characteristic : Single unilateral supratentorial lesion On clinician 's assessment , must operable normal consideration risk vs. benefit condition prognosis 4 . Patient receive conventional treatment time initial diagnosis , include surgery ( biopsy debulking ) , and/or radiotherapy , and/or chemotherapy 5 . Male female ; racial exclusion ; least 18 year age 6 . Pregnancy must exclude female patient beta HCG ( Human Chorionic Gonadotropin ) ; patient agree use adequate contraception study duration , become pregnant father child study 7 . Karnofsky Performance Status least 50 8 . Patients must able understand consent study instruction well follow prescribe instruction 9 . Patient must sign write informed consent prior study participation 1 . Patient must enrol clinical trial 30 day participation trial 2 . History allergic reaction attribute compound similar chemical makeup composition CMBC2 , alginate irinotecan ; contraindication irinotecan therapy 3 . Open communication ventricle CSF ( cerebrospinal fluid ) tumour resection cavity/site must avoid . In case opening ventricle surgery , surgeon must decide whether effective closure possible obstruct gap Gelfoam/other appropriate material 4 . Tumor surgery , stereotactic biopsy high grade glioma , neurosurgery within 30 day prior study entry 5 . Irinotecan chemotherapy within 30 day prior study treatment 6 . Radiotherapy stereotactic ( gamma knife ) radiosurgery within 90 day prior study entry 7 . Locoregional ( intracranial ) therapy treatment high grade glioma , include administration biodegradable polymer wafer contain Carmustine and/or brachytherapy , 6 month prior study entry 8 . Significant liver function impairment : aminotransferase ( AST ) alanine transaminase ( ALT ) great 2.5 x upper limit normal ( ULN ) , total bilirubin great 2 x ULN 9 . Significant renal impairment : creatinine great 2.0 mg/dL 10 . Coagulopathy Prothrombin time ( PT ) partial thromboplastin time ( APTT ) less 1.5 x control , and/or platelet count le 100 x 10⁹/L 11 . Hb le 8 g/dL and/or neutrophil count ( ANC Absolute Neutrophil Count ) less 1 x 10⁹/L 12 . Any condition , investigator 's opinion , make patient 's best interest participate study 13 . Preexisting cerebral oedema , surgeon 's opinion , pose unacceptable risk postoperative oedema . This decision may time surgery . 14 . Presence concurrent malignancy , except adequately control limited basal cell carcinoma skin carcinoma situ cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>